<?xml version='1.0' encoding='utf-8'?>
<document id="20100913"><sentence text="A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis."><entity charOffset="54-63" id="DDI-PubMed.20100913.s1.e0" text="pamapimod" /><entity charOffset="104-116" id="DDI-PubMed.20100913.s1.e1" text="methotrexate" /><pair ddi="false" e1="DDI-PubMed.20100913.s1.e0" e2="DDI-PubMed.20100913.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20100913.s1.e0" e2="DDI-PubMed.20100913.s1.e1" /></sentence><sentence text="This study evaluated the potential pharmacokinetic interaction of pamapimod, a p38 mitogen-activated protein kinase inhibitor, and methotrexate (MTX) when administered concomitantly in patients with rheumatoid arthritis (RA); the study also evaluated the pharmacodynamic effects of pamapimod"><entity charOffset="66-75" id="DDI-PubMed.20100913.s2.e0" text="pamapimod" /><entity charOffset="131-143" id="DDI-PubMed.20100913.s2.e1" text="methotrexate" /><entity charOffset="145-148" id="DDI-PubMed.20100913.s2.e2" text="MTX" /><entity charOffset="282-291" id="DDI-PubMed.20100913.s2.e3" text="pamapimod" /><pair ddi="false" e1="DDI-PubMed.20100913.s2.e0" e2="DDI-PubMed.20100913.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20100913.s2.e0" e2="DDI-PubMed.20100913.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20100913.s2.e0" e2="DDI-PubMed.20100913.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20100913.s2.e0" e2="DDI-PubMed.20100913.s2.e3" /><pair ddi="false" e1="DDI-PubMed.20100913.s2.e1" e2="DDI-PubMed.20100913.s2.e1" /><pair ddi="false" e1="DDI-PubMed.20100913.s2.e1" e2="DDI-PubMed.20100913.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20100913.s2.e1" e2="DDI-PubMed.20100913.s2.e3" /><pair ddi="false" e1="DDI-PubMed.20100913.s2.e2" e2="DDI-PubMed.20100913.s2.e2" /><pair ddi="false" e1="DDI-PubMed.20100913.s2.e2" e2="DDI-PubMed.20100913.s2.e3" /></sentence><sentence text=" Twenty-two RA patients on a stable regimen of MTX (10-25 mg/wk; administered on days 1 and 8) were randomized to receive 300 mg of pamapimod (n = 17) or placebo (n = 5) once daily (qd) for 10 days (days 5-14)"><entity charOffset="47-50" id="DDI-PubMed.20100913.s3.e0" text="MTX" /><entity charOffset="132-141" id="DDI-PubMed.20100913.s3.e1" text="pamapimod" /><pair ddi="false" e1="DDI-PubMed.20100913.s3.e0" e2="DDI-PubMed.20100913.s3.e0" /><pair ddi="false" e1="DDI-PubMed.20100913.s3.e0" e2="DDI-PubMed.20100913.s3.e1" /></sentence><sentence text=" Blood and urine samples were collected pre- and postdose on days 1 (MTX alone), 7 (pamapimod alone), and 8 (MTX and pamapimod coadministered)"><entity charOffset="117-126" id="DDI-PubMed.20100913.s4.e0" text="pamapimod" /><entity charOffset="69-77" id="DDI-PubMed.20100913.s4.e1" text="MTX" /><entity charOffset="109-117" id="DDI-PubMed.20100913.s4.e2" text="MTX" /><pair ddi="false" e1="DDI-PubMed.20100913.s4.e1" e2="DDI-PubMed.20100913.s4.e1" /><pair ddi="false" e1="DDI-PubMed.20100913.s4.e1" e2="DDI-PubMed.20100913.s4.e2" /><pair ddi="false" e1="DDI-PubMed.20100913.s4.e1" e2="DDI-PubMed.20100913.s4.e0" /><pair ddi="false" e1="DDI-PubMed.20100913.s4.e2" e2="DDI-PubMed.20100913.s4.e2" /><pair ddi="false" e1="DDI-PubMed.20100913.s4.e2" e2="DDI-PubMed.20100913.s4.e0" /></sentence><sentence text=" No clinically significant changes were observed in plasma exposures and renal clearance of pamapimod, MTX, or their metabolites, whether administered separately or concomitantly"><entity charOffset="92-101" id="DDI-PubMed.20100913.s5.e0" text="pamapimod" /><entity charOffset="103-106" id="DDI-PubMed.20100913.s5.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.20100913.s5.e0" e2="DDI-PubMed.20100913.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20100913.s5.e0" e2="DDI-PubMed.20100913.s5.e1" /></sentence><sentence text=" The combination of pamapimod (300 mg qd) for 10 days and weekly MTX was generally well tolerated"><entity charOffset="20-29" id="DDI-PubMed.20100913.s6.e0" text="pamapimod" /><entity charOffset="65-68" id="DDI-PubMed.20100913.s6.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.20100913.s6.e0" e2="DDI-PubMed.20100913.s6.e0" /><pair ddi="false" e1="DDI-PubMed.20100913.s6.e0" e2="DDI-PubMed.20100913.s6.e1" /></sentence><sentence text=" Parameters of RA disease--namely, tender joint count, swollen joint count, erythrocyte sedimentation rate, and C-reactive protein--generally decreased between days 5 and 14" /><sentence text=" The results of this study suggest that dose adjustments for either drug are not necessary when concomitantly administered and that pamapimod can decrease pharmacodynamic markers of disease activity"><entity charOffset="132-141" id="DDI-PubMed.20100913.s8.e0" text="pamapimod" /></sentence><sentence text="" /></document>